title: In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
abstract: Adoptive immunotherapy with tumour-reactive CD8(+) cytotoxic T lymphocytes (CTLs) requires efficient in vitro approaches allowing the expansion of CTLs to large numbers prior infusion. Here, we investigated the antigen-independent activation and the expansion of human T cells in peripheral blood mononuclear cells (PBMCs) and in tumour-reactive CTLs using Dynabeads coated with monoclonal antibodies to CD3 and to the costimulatory molecules CD28 and CD137 (4-1BB). T cells in PBMCs showed an increased expansion rate of 15- to 17-fold during a 2-week culture period using antibody-conjugated beads with interleukin-2 (IL-2) added versus IL-2 alone. No significant difference between CD3/CD28 beads and CD3/CD28/CD137 beads was observed (P = 0.4). In contrast, expansion of tumour-reactive CD8(+) CTLs over 2 weeks was more efficient using CD3/CD28/CD137 beads (14.4-fold ± 1.2) compared with CD3/CD28 beads (10.6-fold ± 0.7) (P = 0.03) and matched well to the control arm using weekly stimulation with tumour cells. Although all modes of in vitro stimulation decreased the expression of central memory markers CD62L and CCR7 on CTLs, bead-activated cultures expressed consistently higher levels than tumour-stimulated cultures. CTLs analysed after bead-induced expansion versus weekly tumour stimulation showed equal IFN-γ production in ELISPOT assay. Furthermore, cytotoxicity assays demonstrated an either unchanged or slightly reduced capability of tumour cell lysis for antigen-independent stimulated CTLs versus those that maintained on weekly tumour stimulation, regardless of which type of beads was used. Our data suggest that the conjugation of anti-CD137 antibodies to conventional CD3/CD28 beads results in a minor but significant increase in the expansion capacity for tumour-reactive CD8(+) CTLs.
authors.affiliation: Department of Medicine III, Hematology and Oncology, University Medical Center of Johannes Gutenberg-University, Mainz, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Teschner
authors.forename: G
authors.initials: G
authors.lastname: Wenzel
authors.forename: E
authors.initials: E
authors.lastname: Distler
authors.forename: E
authors.initials: E
authors.lastname: Schnürer
authors.forename: M
authors.initials: M
authors.lastname: Theobald
authors.forename: A A
authors.initials: AA
authors.lastname: Neurauter
authors.forename: K
authors.initials: K
authors.lastname: Schjetne
authors.forename: W
authors.initials: W
authors.lastname: Herr
mesh_terms: D018106:CD28 Antigens / Q000276:immunology*; D017252:CD3 Complex / Q000276:immunology*; D002478:Cells, Cultured; D006801:Humans; D018189:Immunomagnetic Separation; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D007376:Interleukin-2 / Q000276:immunology; D019041:L-Selectin / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology*; D054400:Receptors, CCR7 / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9 / Q000276:immunology*
chemical_list: C515370:CCR7 protein, human; D018106:CD28 Antigens; D017252:CD3 Complex; D007376:Interleukin-2; D054400:Receptors, CCR7; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9; D019041:L-Selectin; D007371:Interferon-gamma